We are very cognizant of the limitations of administrative data pointed out by Dr. Rockey and Dr. Talal and colleagues. Because we did not have access to data that reliably captured all treatment contraindications, we opted not to use treatment contraindications as an explicit exclusion criterion for our treatment receipt indicator. Without a doubt, this limits interpretation of 1 important component indicator of our analysis. However, the prevalence of absolute contraindications to antiviral treatment may not be as high as posited by this comment.